Akeso, Inc.
Research Akeso, Inc. (9926.HK) on Bullrun: market cap HKD 84.10B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker9926.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 84.10B
- Financial periodFY2025
- RevenueCNY 3.06B
- Revenue growth43.9%
- Net income-CNY 1.11B
- Free cash flow-CNY 1.73B
- Gross margin78.7%
Valuation Snapshot
latest market cap is HKD 84.10B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 3.06B | -CNY 1.11B | -CNY 1.73B | 78.7% | -1.23 | CNY 8.78B | CNY 4.56B | CNY 9.05B |
| FY2024 | CNY 2.12B | -CNY 514.52M | -CNY 1.12B | 86.4% | -0.6 | CNY 6.89B | CNY 3.95B | CNY 6.81B |
| FY2023 | CNY 4.53B | CNY 2.03B | CNY 1.59B | 97.1% | 2.42 | CNY 4.03B | CNY 2.99B | CNY 4.69B |
| FY2022 | CNY 837.66M | -CNY 1.17B | -CNY 2.04B | 88.8% | -1.42 | CNY 2.09B | CNY 1.88B | CNY 2.64B |
| FY2021 | n/a | n/a | n/a | n/a | -1.32 | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 84.10B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About Akeso, Inc.
Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, and liver cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell carcinoma, breast cancer, colorectal cancer, and pancreatic cancer.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Akeso, Inc.'s market cap?
Akeso, Inc.'s market capitalization is HKD 84.10B.
What does Akeso, Inc. do?
Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, and liver cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell carcinoma, breast cancer, colorectal cancer, and pancreatic cancer.